Many biotech stocks now costing a lot of funds even for hedge funds. Only some of the COVID-19 vaccine developing stocks may cost less than $20 temporarily as one news article from PR sites can triple their shares within one day.
Sorrento’s STI-1499 in antibody cocktail is the main solution to neutralize the COVID-19. Right now it is still being tested clinically. If there is progress in the development of the cocktail Sorrento Therapeutics (NASDAQ: SRNE) will definitely soar. Having some SRNE shares could make one filthy rich near future.
$12.28 price of SRNE is very low as compared to Moderna, Pfizer, and Novavax shares. So, any newbies may join this crowd now before it jumps higher so rich investors may afford it.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.